Lupin Gets USFDA Approval for Generic Seizure Medication

Jul 12, 2024 17:31

Lupin has received USFDA approval to market a generic version of Topiramate extended-release capsules for the treatment of seizures in patients aged 6 and older.

New Delhi, Jul 12 (PTI) Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.

The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.

The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.

Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.

As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.

Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.

Source: PTI

MORE NEWS

Unilever: India Growth & GST Impact

Unilever sees huge opportunities in India due to high GDP growth and GST cuts. HUL...

Trai Recommends 6 GHz, E, V Band Allocation

Trai suggests administrative allocation of 6 GHz, E, and V bands for telecom backhaul....

TotalEnergies Sells Stake in Adani Green Energy

TotalEnergies sells 1.74% stake in Adani Green Energy for Rs 2,778 cr. Stake reduced to...

TCS Acquires Coastal Cloud for $700 Million

TCS acquires Coastal Cloud for USD 700 million, strengthening its Salesforce and AI...

JSW Paints Acquires AkzoNobel India Stake

JSW Paints completes acquisition of majority stake in AkzoNobel India, becoming the...

Park Medi World IPO Subscribed 52% on Day 1

Park Medi World''s IPO received 52% subscription on day 1. The Rs 920-crore IPO closes...

Dasnac Invests Rs 2,000 Cr in Noida Luxury Housing

Dasnac to invest Rs 2,000 crore in a luxury housing project, Dasnac Westminster, in...

Nephrocare IPO Subscribed 12% on Day 1

Nephrocare Health Services IPO received 12% subscription on day 1. IPO details, price...

Wakefit IPO Subscribed Over 2 Times

Wakefit''s Rs 1,289-cr IPO was subscribed over 2 times on the final day. Details on...

IAN Group to Deploy USD 100M Alpha Fund by 2027

IAN Group to deploy its USD 100 million IAN Alpha Fund in early-stage startups by 2027....

Lupin Gets USFDA Approval for Generic Seizure Medication

You May Like To Read

MORE NEWS